Zai Lab Stock Soars 15% on Clinical Breakthrough!

miércoles, 4 de junio de 2025, 11:08 am ET1 min de lectura
ZLAB--
Zai Lab Limited surged 15.10% intraday, driven by positive clinical data for ZL-1310 presented at the 2025 ASCOASC-- conference, showing strong anti-tumor activity and safety, particularly in late-stage small cell lung cancer patients. Additionally, the overall strong performance of the Hong Kong biotech sector and rising investor confidence in innovative drug companies contributed to the price movement.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios